New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime ...
The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
Updated initial conversion table based on clinical trials in adults showing significantly improved mealtime glycemic ...
MannKind (Nasdaq:MNKD) announced today that it received FDA approval, updating the prescribing information for Afrezza ...
ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results